Maha Othman: Redefining Hemostasis Through AI-Enabled Peptide Engineering
Maha Othman, Co-Chairman SSC on Disseminated intravascular coagulopathy at International Society on Thrombosis and Haemostasis, shared
Seminars in Thrombosis and Hemostasis‘s post on LinkedIn, adding:
“Delighted to see this published.
Proud of my mentee Thomas Kazmirchuk and collaborator Ashkan Golshani
Look forward to continuing this research to drive innovation towards understanding of disease pathophysiology, diagnosis, and management, especially for the rare bleeding disorders!”
Seminars in Thrombosis and Hemostasis shared a post on LinkedIn about a recent article by Thomas Kazmirchuk et al., adding:
“Excited to share this insightful article on how AI-driven peptide design is shaping the future of hemostasis and precision medicine for bleeding disorders.
A promising step toward more targeted and personalized therapies.”
Title: Designing the Future of Hemostasis
Authors: Thomas D. D. Kazmirchuk , Jiashu Wang, Janice Corbette, Zein Al Abideen Hammad, Maha Othman, Ashkan Golshani
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 13:29Factor XI Deficiency and the Challenge of Unpredictable Bleeding – EHC
-
Sep 20, 2026, 13:18Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
-
Sep 20, 2026, 13:08Mohammad Salar Amoli: When Routine Coagulation Tests Miss von Willebrand Disease
-
Sep 20, 2026, 12:55Stelios Andreadis։ Human Salivary Gland Organoids Offer New Potential for Regenerative Medicine
-
Sep 20, 2026, 12:43Obi Light Ogbonnia: The Power of Lived Experience in Sickle Cell Care
-
Sep 20, 2026, 12:34Sabrine Mekni: Advancing HSCT for Children With Fanconi Anemia
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI